US Defense Secretary Proposes Testosterone Screening for Military Personnel Amid Medical Criticism
Pete Hegseth’s plan to screen service members aged 30 and older for hormone levels has drawn sharp rebuke from Johns Hopkins University researchers who label the initiative “junk science” due to unproven performance benefits and significant health risks.
US Defense Secretary Pete Hegseth has announced a policy requiring annual testosterone screenings for military personnel aged 30 and older, with voluntary hormone replacement therapy offered to those with deficient levels. The proposal, detailed in a video posted to his official X account, frames the initiative as a measure to restore a “warrior ethos” and optimise natural capabilities. Hegseth stated the program is not about artificial enhancement but rather protecting longevity and ensuring biological foundations for combat readiness, though he provided no evidence that the screenings would improve performance, resilience, or long-term health.
Medical experts have strongly criticised the proposal. Adrian Dobs, an endocrine researcher at Johns Hopkins University, described the plan as “junk science” and “misinformed,” citing the complexity of diagnosing male hypogonadism. Dobs highlighted that testosterone levels fluctuate significantly due to circadian rhythms, typically peaking in the morning and declining throughout the day. She also noted that standard diagnostic practice requires identifying and treating underlying conditions, such as kidney or liver disease, before considering hormonal intervention, rather than using testosterone replacement as a primary solution.
The potential health risks associated with testosterone replacement therapy (TRT) were also a focal point of the criticism. Dobs warned that exogenous testosterone can cause testicular atrophy and reduced sperm count, effects that may not reverse after cessation. She further noted that the therapy can thicken the blood, increasing cardiovascular strain. These concerns are particularly relevant for service members in their twenties and thirties, who are often at the peak of their fertility, yet the Pentagon declined to comment on the scientific basis for the policy or the specific metrics for success.
The announcement aligns with a broader pattern of policy changes under Hegseth’s tenure, which has included purging transgender service members, imposing male-standard fitness tests, and blocking promotions for women and people of colour. Most recently, the Navy announced it would cease issuing permanent shaving waivers for conditions like pseudofolliculitis barbae, a condition disproportionately affecting Black service members. Critics argue these measures reflect a masculinist philosophy rather than practical military objectives, with no concrete data provided to justify the testosterone directive’s impact on combat effectiveness.
While TRT can be effective for specific medical conditions such as genetic abnormalities or pituitary tumours, experts caution against its use as a general performance enhancer. The push for widespread screening has drawn parallels to the views of public figures like Joe Rogan and Health Secretary Robert F. Kennedy Jr., who advocate for TRT despite limited scientific consensus on its benefits for healthy individuals. As the Pentagon moves forward with the screenings, the absence of a clear definition of success or robust scientific backing leaves the policy’s practical utility in question.
